BRISTOL MYERS SQUIBB CO (CELG-RI) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.10

From 52W high−47.59%

Volume6024.00

Market cap$223.74M

P/E (TTM)0.0x

P/S (TTM)0.0x

Div yield—

Key dataNov 4, 2026

Open

$0.10

From 52W high

−47.59%

Volume

6024.00

Market cap

$223.74M

ValuationView details →

P/E (Fwd)

0.0x

EV/EBITDA

2.1x

P/E (TTM)

0.0x

RSI (14)

49.6

MomentumView details →

1D Return

+0.73%

YTD Return

+52.99%

SummaryUpdated Sep 1, 2026

Bristol-Myers Squibb Company (NYSE:BMY) is a major American pharmaceutical corporation founded in 1933 through the merger of Bristol-Myers Company and E.R. Squibb & Sons. Headquartered in Princeton, New Jersey, the company has evolved into one of the world's leading biopharmaceutical companies, focusing on the discovery, development, and commercialization of innovative medicines for serious diseases. Over its nine-decade history, Bristol-Myers Squibb has built a reputation as a pioneer in oncology, immunology, cardiovascular disease, and fibrosis treatments, with a particular emphasis on transforming patient outcomes through cutting-edge therapeutic approaches.

Ask drillr about BRISTOL MYERS SQUIBB CO →

ValuationView details →

P/E (Fwd)

0.0x

P/E (TTM)

0.0x

EV/EBITDA

2.1x

EV/Sales

0.6x

P/S (TTM)

0.0x

P/B (TTM)

0.0x

ProfitabilityView details →

Gross Margin

69.24%

Net Margin

18.47%

EBITDA Margin

30.28%

ROE (TTM)

39.49%

ROA (TTM)

10.41%

Asset Turnover

0.57x

GrowthView details →

Revenue YoY

+4.16%

EPS YoY

+52.42%

FCF YoY

−39.32%

Revenue CAGR 3Y

+1.45%

EPS CAGR 3Y

+5.22%

EBITDA YoY

+1.13%

MomentumView details →

1D Return

+0.73%

YTD Return

+52.99%

1Y Return

+222.58%

RSI (14)

49.6

vs 50D SMA

−4.82%

vs 200D SMA

+1.13%

Capital & dividendView details →

Debt/Equity

1.91x

Current Ratio

1.59x

Quick Ratio

1.44x

Div Yield

—

Div Rate

—

Div Growth 1Y

−80.97%

EarningsView details →

EPS (Actual)

$1.06

EPS Surprise

−38.37%

Beats (12Q)

2/12

Next Q EPS Est

$1.59

Avg Surprise (4Q)

−14.07%

Rev Surprise

3.80%

Financials snapshotView financials →

Revenue (TTM)

50.03B

Net Income (TTM)

9.24B

Op. CF (TTM)

10.65B

Latest newsMore news →

BRISTOL MYERS SQUIBB CO said it will not advance PRX019 into clinical development.6d ago

VEEVA SYSTEMS INC announced that executives from ASTRAZENECA PLC, BRISTOL MYERS SQUIBB CO, Grünenthal GmbH, NOVO NORDISK A S, Roche Holdings, Inc. and UCB SA are among those featured at Veeva Summit, which presents innovations in AI and data for an agent-based commercial model.6d ago

Similar companies

Modern Chinese Medicine Group Co., Ltd.01643.HK Beijing Biostar Pharms Co Ltd02563.HK Citius Oncology, Inc.CTOR TYK Medicines, Inc02410.HK Fangzhou Inc.06086.HK MIRA Pharmaceuticals, Inc.MIRA Find similar companies →

Latest newsMore news →

BRISTOL MYERS SQUIBB CO said it will not advance PRX019 into clinical development.6d ago VEEVA SYSTEMS INC announced that executives from ASTRAZENECA PLC, BRISTOL MYERS SQUIBB CO, Grünenthal GmbH, NOVO NORDISK A S, Roche Holdings, Inc. and UCB SA are among those featured at Veeva Summit, which presents innovations in AI and data for an agent-based commercial model.6d ago